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DIAGNOSTIC TEST AND THERAPY FOR 
MANGANESE SUPEROXIDE DISMUTATE 
(MNSOD) ASSOCIATED DISEASES 
RELATED APPLICATION 
This application claims priority from Provisional Patent 
Application Serial No. 60/119,188 ?led Feb. 8, 1999 entitled 
“DIAGNOSTIC TEST AND THERAPY FOR MANGA 
NESE SUPEROXIDE DISMUTATE (mNsod)ASSOCIATE 
DISEASES, the entire disclosure of Which is hereby incor 
porated by reference herein. 
STATEMENT AS TO RIGHTS TO INVENTIONS 
MADE UNDER FEDERALLY SPONSORED 
RESEARCH AND DEVELOPMENT GRANTS 
This invention Was made With Government support under 
NIH grants CA 49797, CA 59835, and HL 03544, as Well as 
grants from the Environmental Protection Agency. The 
Government has certain rights in this invention. 
TECHNICAL FILED OF THE INVENTION 
The present invention relates to a diagnostic test and 
diagnostic kit for disease associated With decreased super 
oxide dismutase transcriptional activity. The present inven 
tion also relates to method of treating such diseases by 
augmentation of superoxide dismutase levels in affected 
tissues and cells. 
BACKGROUND OF THE INVENTION 
Aerobic organisms possess antioxidant defense systems 
that modulate reactive oxygen species (ROS). The superox 
ide dismutase (SODs) catalyZe the dismutation of superox 
ide radicals into hydrogen peroxide and molecular oxygen. 
Hydrogen peroxide is further detoxi?ed by catalase and 
glutathione peroxidase (HalliWell and Gutterbridge, 1989). 
Three distinct SODs are found in human cells; a mon 
odimeric cytosolic CuZnSOD (McCord and Fridovich, 
1969); an extracellular homotetrameric glycosylated CuZn 
SOD (ECSOD) (Marklund, 1982); and a mitochondrial 
matrix homotetrameric MnSOD (Weisiger and Fridovich, 
1973). 
Accumulating data suggest that MnSOD constitutes one 
of the major cellular defense mechanism against the toxic 
effects of agents that cause oxidative stress. It has been 
demonstrated that MnSOD knockout mice develop cardi 
omyopathy and neonatal lethality, Whereas independent dis 
ruption of the genes for CuZnSOD and ECSOD isoenZymes 
result in viable, normal mice under nonstress conditions 
(revieWed in Yen and St. Clair, 1997). Furthermore, trans 
genic mice expressing human MnSOD in the mitochondria 
are protected from oxygen-induced cardiac injury (Yen et 
al., 1996), and ischemia-induced brain injury (Keller et al., 
1998). 
Numerous studies using gene transfection have demon 
strated that transfection of MnSOD into tumor cells reverse 
the malignant phenotypes of tumor cells, suggesting that 
MnSOD functions to suppress tumorigenicity (revieWed in 
St. Clair et al., 1997). Transfection of human MnSOD cDNA 
into mouse ?broblasts prevents radiation-induced neoplastic 
transformation (St. Clair et al. 1992). Expression of the 
human MnSOD gene in mouse C3H10T1/2 cells enhances 
cellular differentiation upon treatment With 5-aZacytidine 
(St. Clair et al. 1994). The malignant phenotype of human 
melanoma cells Was suppressed by introduction of human 
chromosome 6 Where the MnSOD gene is located (Trent et 
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al. 1990) or transfection of a human MnSOD cDNA (Church 
et al., 1993). Overexpression of MnSOD suppressed the 
malignant phenotypes of human breast cancer cells (Li et al. 
1995), human glioma cells (Zhong et al., 1997), and mouse 
epidermal cells (Amstad et al., 1997). The number of cells 
required to produce tumors in syngenic mice Was markedly 
increased for the MnSOD-transfected murine ?brosarcoma 
cells lines (MnSOD-Fsa-II) compared to the vector 
transfected control cells (St. Clair et al., 1997). The fre 
quency of metastases Was reduced in syngenic mice carrying 
the MnSOD transfected-FsaII cells compared to the mice 
bearing the control FsaII cells (Stafford et al., 1994). Fur 
thermore the radiation dose required to control one-half of 
the irradiate tumor (TCD50) Was greatly reduced When the 
MnSOD-FsaII cells Were transplanted and irradiated in vivo 
under hypoxic conditions (Urano et al., 1995). Taken 
together, the evidence from these studies supports a hypoth 
esis proposed by Oberley and Oberley (1984) that MnSOD 
plays an important role in the prevention of cancer devel 
opment. 
It has been shoWn that many types of human cancer cells 
have reduced MnSOD activity compared to their appropriate 
normal counterpart cells; (oberley and Buettner, 1979). The 
reduced level of MnSOD activity in human cancer cells is 
not due to a defect in the primary structure of the MnSOD 
protein, a change in the dosage of the MnSOD gene, or a 
decrease in the stability of MnSOD mRNA in tumor cells, 
but rather is due to defects in the expression of the gene (St. 
Clair and Holland, 1991). 
The present inventors previously cloned and sequenced 
the entire human MnSOD gene, including a 0.7 kb 5‘ 
?anking region, from a genomic library obtained from 
normal human lung ?broblast cells. The gene is character 
iZed by the lack of TATA or CAAT box regulatory elements 
and the presence of a GC-rich region containing multiple 
SP-1 binding sites (Wan et al., 1994). 
Prior research has failed to elucidate the cause for reduced 
expression of MnSOD in tumor cells. The present inventors 
have undertaken extensive research in order to solve this 
problem, and have accomplished this result by discovering 
several highly conserved mutations in the promoter region 
of the MnSOD gene. 
In order to elucidate the cause for the reduced expression 
of human MnSOD in tumor cells, the present inventors have 
noW further sequenced the 5‘ ?anking region of the human 
SOD gene and compared that to the 5‘ ?anking region of the 
human MnSOD gene from several tumor cell lines. The 
results demonstrate three heteroZygous mutations n the 
promoter region of the human MnSOD gene in 5 of 14 tumor 
cell lines examined. Signi?cantly these mutations Were 
conserved amongst 3 of 5 colon cancer cell lines studied. 
The effect of these mutations on the transcription activity of 
the human MnSOD promoter Was also determined by means 
of a reporter gene constructs. These results demonstrated 
markedly reduced gene expression When compared to tran 
scriptional activation of the normal, Wild-type MnSOD 
promoter. 
An object of the present invention is to provide a diag 
nostic kit and a diagnostic method for assaying the presence 
of superoxide dismutase gene mutations associated With 
decreased enZyme activity seen in many diseases. 
Speci?cally, this invention aims at providing a diagnostic kit 
and method for certain cancers associated With reduced 
MnSOD expression. Another object of the present invention 
is to provide a diagnostic test and a diagnostic kit for 
Amylotrophic Lateral Sclerosis, ALS, Which his also asso 
ciated With reduced MnSOD activity. 
US 6,265,172 B1 
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Another objection of the present invention is to provide a 
therapeutic method targeted at disease associated With 
decreased MnSOD activity, and more speci?cally targeted at 
cancer and ALS. 
SUMMARY OF THE INVENTION 
It is one of the principal objectives of the present inven 
tion to provide a diagnostic kit and a diagnostic test for the 
detection of MnSOD mutations associated With various 
diseases. It is a further object to provide such a diagnostic kit 
and method for cancer. The present invention provides an 
assay Which detects mutations in the regulatory region of 
MnSOD gene by a variety of methods comprising RFLP 
analysis, in conjunction With PCR ampli?cation or DNA 
hybridiZation (Southern Blotting) utiliZing a labeled oligo 
nucleotide probe complementary to the MnSOD promoter/ 
enhancer. 
The present invention also provides a therapeutic method 
directed to MnSOD associated diseases Which comprises 
augmentation of MnSOD activity by transfection of affected 
cells or tissues With high activity MnSOD expression 
vectors, or administration of exogenous MnSOD enZyme of 
these sites. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The ?le of this patent contains at least one draWing 
executed in color. Copies of this patent With color draWing 
(s) Will be provided by the Patent and Trademark Office 
upon request and payment of the necessary fee. 
FIG. 1 is a schematic representation of the human 
MnSOD gene and sequencing strategy for the 5‘ ?anking 
region of the gene. Physical map With restriction endonu 
cleases BamH I, EcoR I and Kpn I is illustrated (top), 
shoWing a 3.4 kb 5‘ ?aking region, 5 exons separated by 4 
introns, and 1.36 kb 3‘ ?anking region. The exons/coding 
sequences are depicted With black boxes. The transcription 
initiation site and poly-A are marked With arroWs. A BarH I 
fragment containing the 5‘ ?anking region Was subcloned in 
M13 pm18 or M13 and mp19 vectors and sequenced in both 
directions (bottom). 
FIGS. 2A and 2B represent the DNA sequence of the 5‘ 
?anking region of the human MnSOD gene. The transcrip 
tion initiation site is numbered as +1. Sequences are num 
bered relative to the transcription initiation site (+1). Poten 
tial transcription regulatory binding sites for NF-xB, ARE, 
AP-1, SP-1 and AP-2 are boxed. The arroW heads indicate 
the strand by Which consensus sequences are detected. 
FIG. 3 is a diagram of transcription factors binding ties in 
the 5‘ ?anking region of the human MnSOD gene and 
ampli?cation of the 5‘ ?anking region by polymerase chain 
reaction (PCR). Corresponding transcription factors binding 
sites for NF-xB, ARE, AP-1, AP-2, and SP-1 in the 5‘ 
?anking region are marked (top). Four PCR primer sets Were 
designed for amplication of the 5‘ ?anking region from the 
tumor cell lines (bottom). 
FIG. 4 is a DNA sequence analysis of the cloned PCR-4 
products from the tumor cell lines. A. The Wild type 
sequence isolated from W138. B. Mutations in 5 tumor cell 
lines are identi?ed at the indicated positions. C changes to 
T at —102, C changes to G at —38 and A is inserted at —93. 
FIG. 5 is the direct sequence of PCR product for deter 
mination of a heteroZygosity at each mutation site in the 
tumor cell lines. A. indicates C to T transition at —102 and 
an insertion of A at —93. B. indicates C to G transversion at 
—38. ArroWs indicate the positions of the mutations. 
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FIG. 6 is an analysis of restriction fragment length poly 
morphisms (RFLP) of the promoter region. The C to T 
mutations at —102 results in the loss of Apa I site in the 
tumor cell lines. The mutation at APAI site yield at 246 bp 
uncut fragment comparing to tWo smaller fragments (138 
and 108 bp) from Apa I digestion. 
FIG. 7 demonstrates the effect of mutations in the human 
MnSOD promoter on gene expression. Human ?broblast 
cells Were transfected With (A) plasmids cloned in a pGL 3 
basic vector containing he human MnSOD promoter and 
?re?y luciferase reporter gene; (B) plasmids cloned in a 
pGL3E vector, modi?ed from pGL3 basic vector by addition 
of SV4C enhancer n 3‘ ?anking region of the luciferase gene. 
Activities Were normaliZed by a co-transfected rellina 
luciferase to correct for variations in transfection ef?cien 
cies. 
**Signi?cant difference in transcription activities com 
pared to the normal promoter (p<0.01). 
FIG. 8 is the DNAse I footprinting analysis of the human 
MnSOD promoter using SP-1 and AP-2 proteins. A, P7 (a 
normal promoter fragment), —210 to +24) no protein control; 
B, HT29 (the corresponding fragment from the HT29 cancer 
cell line) no protein control; C, P7 With SP-1 protein; D, 
HT29 With SP-1 protein; E, P7 With AP-2 protein; F, HT29 
With AP=2 protein. The binding patters of SP-1 and AP-2 are 
indicated on the right. (+) represents an additional AP-2 site 
found only in the mutant promoter. 
FIG. 9 Putative cruciform structure With 11-guanine 
unpaired loop located in the human MnSOD promoter. 
Three SP-1 and one AP-2 binding sites located in the 
DNA-looping structure are marked. Sites Where mutations 
may disrupt the proposed structure are indicated. 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS 
The invention may best be understood With reference to 
the accompanying ?gures Wherein an illustrative embodi 
ment is shoWn and in the folloWing detailed description of 
the preferred embodiments. 
The present invention provides a diagnostic method for 
detection of mutations in the MnSOD gene. This detection 
method comprises restriction fragment length polymor 
phism (RFLP) analysis or direct sequencing of the regula 
tory region of MnSOD folloWing extraction of DNA isolated 
from cells or tissues to be assayed. This detection method 
may also comprise mobility shift assays Which involve 
comparison of the electrophoretic mobility of naked DNA 
comprising promoter region sequences to the mobility of 
such a sequence after it is combined With transcription 
factors in-vitro, under conditions Which facilitate the bind 
ing of DNA to protein. The detection method may further 
comprise DNAse footprinting assays, Which ascertain 
Whether the sequence in question has a transcription factor 
binding pattern different from the Wild type sequence. 
Another embodiment of the present diagnostic method may 
also comprise isolation of the MnSOD regulatory region of 
the sample to be tested and subclonining such region into 
plasmid constructs upstream of a suitable reporter gene. 
Reporter gene activity of the sample construct is then 
compared to reporter gene transcriptional activity of a 
control construct driven by a Wild-type promoter. Decreased 
reporter gene activity Will indicate MnSOD promoter muta 
tion. 
The present invention further provides a therapeutic 
method for treating diseases associated With decreased 
MnSOD activity, Which method comprises transfection With 
MnSOD. 
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The present inventors have identi?ed a set of three 
mutations found in ?ve of fourteen cancer cell lines tested, 
clustered around the GC rich region Within a fragment from 
—210 to +24 (relative to transcription initiation site) of the 
MnSOD promoter (FIG. 4). The present inventors have 
demonstrated that these mutations affect transcription factor 
binding (by DNAse Footprinting assays) and transcriptional 
activity (by means of subcloning into a luciferase reporter 
gene construct). This region contains elements recogniZed 
by the transcription factors SP-1 and AP-2, suggesting that 
the decreased MnSOD activity associated With these cancers 
may be modulated by alteration of SP-1 and AP-2 binding 
af?nities. 
Isolation of Genomic NA 
The present inventors isolated genomic DNA for use in 
the present invention assays by means of a commercially 
available DNA extraction kit (Stratagene), according to the 
manufacturer’s instructions. HoWever, any standard proto 
col may be used. Although cancer cell lines Were utiliZed in 
this experiment (Table 1), a similar protocol, and the method 
Which this invention teaches, is suitable for assay of cells of 
any origin including cells derived from patient biopsies. In 
brief, approximately 10“ cells in 300 ml of PBS Were lysed 
by adding pronase to a ?nal concentration of 400 pig/ml and 
folloWed by a 30 minute incubation at 60° C. Cellular 
protein Was removed by salt precipitation and centrifugation 
at 2000><g for 15 min. at 4° C. RNA Was removed by 
incubation of the solution for 30 min. at 37° C. With RNase 
at a ?nal concentration of 25 pig/ml. The DNA Was recovered 
by ethanol precipitation, estimated spectrophotometrically 
and stored at 20° C. 
Ampli?cation of the 5‘ ?anking region of the human 
MnSOD gene by polymerase chain reaction (PCR). A total 
of four PCR primer sets Were designed to amplify a 3.4 kb 
5‘ ?anking region of the human MnSOD gene (FIG. 3). The 
oligonucleotide sequences of the primer sets Were as fol 
lows: 
PCR-1 (—3322 to —1813), 
5‘GCACATCACTTCAGTCTAGGAGT-3‘ (SEQ ID 
N011) and 5‘—GGCTAGTTAGGAAGCTGGTAC-3‘ 
(SEQ ID N012); 
PCR-2 (—1892 to 1093), 
5‘—TCCAGTTCTCATAGCTAGTGCC-3‘ (SEQ ID 
N013) and 5‘-ATATGATGGAAGGTAGCAGGTGC-3‘ 
(SEQ ID N014); 
PCT-3 (—1182 to —242), 
5‘—TTACCGGAAGCCTAGTCATCCTT-3‘ (SEQ ID 
N015) and 5‘—TGCCTGTCTGCCGTACTTGAG-3‘ 
(SEQ ID N016); 
PCR-4 (—321 to 70), 
5‘-GCCTTCGGGCCGTACCAACTCCAA-3‘ (SEQ ID 
N 0 1 7) a n d 
5‘-CTAGTGCTGGTGCTACCGCTGATGC-3‘ (SEQ 
ID N018). 
A highly ?delity pfu DNA polymerase (Stratagene) Was 
used to minimize the error rate in the DNA synthesis by PCR 
(Flagman et al., 1994). PCR Was carried out in 50 pl reaction 
mixture containing 20 mM Tris-CHl, pH 8.8, 2 mM 
MgS004, 10 mM Kcl, 10 mM (NH4)2S04, 0.1% Triton 
X-100, 1 mg/m, nuclease-free BSA, 80 pM each of dAT P, 
dGTP, dCTP, and dTTP, 0.2 pM of each primer, 6% DMSO, 
1 pg genomic DNA, and 2.5 pfu DNA polymerase. The 
thermal cycling settings for PCR-1, PCR-2 and PCR-3 
include a 5 min initial denaturation at 95° C. folloWed by 35 
ampli?cation cycles (1 min denaturation at 94° C., 1 min 
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annealing at 55 to 65° C. depending on the primer sets, and 
1.5 to 3 min. extension at 75° C. depending on the length of 
PCR products, ?nished With a ?nal extension at 72° C. for 
10 min). 7-deaZa-2‘-dGTP (C7 dGTP, Boehringer 
Mannheim) Was used to amplify the PCR-4 because of its 
GC rich nature (Innis et al, 1990). For ampli?cation of PCR 
4, the conditions Were changed to, 311 C7 dGTP1dGTP 
instead of dGTP in the dNTP mixture and 160 pM dNTP: 
Thermal cycling settings include initial denaturation at 98° 
C. for 10 min, 5 cycles of 95° C. for 45 sec, and 72° C. for 
1 min for primer annealing, folloWed by 35 cycles consisting 
of denaturation at 95° C. for 45 sec, annealing at 60° C. for 
1 min, extension at 72° C. for 1.5 min (auto segment 
extension of 2 sec per cycle), and ?nal extension at 72° C. 
for 10 min. The PCR products Were analyZed by on a 1% 
agarose gel in Tris-acetate buffer With ethidium bromide 
staining. The products of PCR-1, PCR-2 and PCR-3 Were 
puri?ed from the agarose gels using a GeneClean Kit 
(Bio101) and the product of PCR-4 by a MC membrane 
(Millipore) according to the manufactures’ recommenda 
tions. 
Cloning 
To determine the nucleotide sequence of the 5‘ ?anking 
region of the human MnSOD gene, a BamIII fragment (B7) 
containing a 3.4 kb 5‘ ?anking region Was subcloned into 
M13mp18 from the 39b 9» clone. This 9» clone Was derived 
from a genomic library prepared from human lung ?broblast 
cells and has been described previously (Wan et al., 1994). 
This 9» clone includes a complete coding region of the human 
MnSOD gene in addition to a 5‘ ?anking region and a 3‘ 
?anking region (Wan et al., 1994). The B7 region Was 
mapped by restrictions endonuclease digestion. Small frag 
ments obtained from the digested B7 Were subcloned into 
multicloning sites of M13 mp18 and/or M13 mp 19 vectors 
for DNA sequencing. 
To clone PCR products ampli?ed from the 5‘ ?anking 
region of human MnSOD gene, a PCR-Script Amp SK(+) 
vector (Stratagene) Was used. The vector Was derived form 
the pBluescript+ II SK (+) phagemid by addition of an Srf 
I site, Which is a rare-cleavage restriction enZyme Within the 
multiple cloning sites. Srf I recogniZed 8 bp oligonucleotide 
sequence 5‘-GCCC/GGGC-3‘ and its cutting site is the same 
as Sma I (5‘-CCC/GGG-3‘). The use of Srf I in the ligation 
maintains the concentration of Sma I digested vector DNA 
by preventing self-ligation of the vector and alloWs rapid 
and ef?cient blunt-ended cloning of the PCR products 
ampli?ed by pfu DNA polymerase. Screening of the PCR 
products Was performed by the blue-White phenotype from 
a-complementation of lac Z gene and restriction pattern of 
the recombinant plasmids. For DNA sequencing, the plas 
mid DNA Was prepared from 1.5 ml of LB culture and 
puri?ed by polyethylene glycol 800 precipitation. 
Sequence Analysis 
To determine the DNA sequence in the 5‘ ?anking region 
of the human MnSOD gene, single-strand DNA templates 
Were prepared from M13 clones and the nucleotide 
sequences Was determined on both strands by Sanger’s 
dideoxynucleotide chain-termination method (Sanger et al., 
1977) With Sequenase 2.0 (Amersham). AdITP reaction mix 
Was used to sequence the GC rich region. Multiple overlap 
ping fragments Were sequenced at least tWice in each 
direction (FIG. 1) and the DNA sequence Was analyZed by 
MacVector softWare (Kodak) and potential transcription 
factor binding sites mapped (FIG. 2). 
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To investigate mutations in the 5‘ ?anking region, thirty 
four oligonucleotides complementary to de?ned DNA 
sequences of the 5 ‘ ?anking region Were synthesized as DNA 
sequencing primers in both forWard and reverse directions. 
DNA sequence analysis Was performed by manual method 
(Thermo sequenase cycle sequencing kit, Amersham) and 
automatic sequence method (Applied biosystem) according 
to the manufacturers instructions (FIG. 4). Direct sequenc 
ing of PCR products Was performed to con?rm that the 
detected mutations are heteroZygous in nature. 7-deaZa 
dGTP and 10% DMSO Were used for sequencing the GC 
rich region (FIG. 5). 
Computer analysis predicted that the mutations Would 
alter recognition site for several restriction endoucleases 
(Table 2). The Ainsertion at —93 and the C to G transversion 
at —38 Would create a neW Mnl I (CCTCN7) and an Aha I 
(CCSGG) restriction digestion sites respectively. HoWever, 
the C to T transition at —102 Would result in loss of the Apa 
I (GGGCCC) restriction digestion site. To verify these 
predictions, analysis of restriction fragment length polymor 
phisms (RFLP) Was performed to compare restriction diges 
tion patterns in the tumor and normal cells. 
RFLP Analysis 
Analysis of restriction fragment length polymorphisms 
Was used to con?rm the changes of restriction enZyme 
digestion sites caused by the mutations (FIG. 6). The cloned 
mutated and non mutated PCR products Were cut With 
appropriate restriction enZymes, subjected to electrophoresis 
through a 2% agarose gel in Tris-borate buffer, stained With 
ethidium bromide, and photographed. 
The present RFLP analysis utiliZed Apa I. While treat 
ment of the normal fragment spanning —210 to +24 yielding 
tWo bands of 138 bp and 108 bp siZe folloWing restriction 
enZyme digestion; the mutated fragment yielded only one 
band of 24 bp due to loss of the Apa I site (FIG. 6). It Would 
also be feasible to perform such RFLP analysis With Aha I 
or Mnl I. Indeed, any mutation Within the 5 ‘ promoter region 
Would be eXpected to result in loss or addition of a variety 
of different restriction enZyme recognition sites. Thus, other 
mutations in the 5‘ promoter region could be detected by 
using the appropriate restriction enZyme for RFLP analysis. 
Moreover, although the present RFLP analysis utiliZed 
ethidium bromide staining for detection, it is also feasible to 
utiliZe Southern blotting according to standard protocols, 
Wherein folloWing gel electrophoresis, the DNA is trans 
ferred to a suitable membrane such as nylon, and af?Xed by 
baking or crosslinking. Then a labeled oligonucleotide 
probe, complementary to a MnSOD promoter sequence 
Would be alloWed to hybridiZe to the adsorbed DNA 
fragments, and detection is accomplished by eXposing the 
membrane to 2-ray ?lm. 
Analysis of the Promoter Activities 
A luciferase reporter system (Promega) Was used to 
determine changes of the promoter activity due to mutations 
in the human MnSOD promoter (FIG. 7). Plasmid constructs 
Were prepared using pGL3-Basic and pGL3-SV40 enhancer 
vectors to subclone each promoter region upstream of the 
?re?y luciferase reporter gene. A set of PCR primers With 
recognition sequences of Kpn I and Bgl II digestion on the 
terminals Was used to amplify the promoter region —154 to 
+24 from the cloned PCR-4 products. The sequences of 
oligonucleotide primers Were: 
5‘-CGGGGTACCACAGGCACGCAGGGCACCCCCGG 
GGT-3‘ (SEQ ID N019) and 5‘-GGAAGATCT 
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GCCGAAGCCACCACAGCCACGAGT-3‘ (SEQ ID 
NO:10). The PCR condition Was the same as that described 
for the PCR-4. The PCR products Were cloned into the 
luciferase reporter vectors Within Kpn I and Bgl II sites. 
The resulting plasmids Were transiently transfected into 
the VA13 cells by the calcium phosphate mediated trans 
fection method (Wigler et al., 1977). To control for differ 
ences in transfection ef?ciencies, an additional vector 
(Renilla luciferase, co-vector) Was co-trasfeted(???) as an 
internal control. A mixture of 3.6 pg vector DNA and 0.4 pg 
co-vector DNA (10:1) Was transfected into the cells (Which 
had been plated at a density of 1><10(????) cells and incu 
bated at 37 degrees Celsius for 16 hours prior to 
transfection) in a 32 mm tissue culture dish. SiXty hours after 
transfection, the cells Were Washed With PBS 3 times, 
harvested,and lysed by incubation With 200 pl passive lysis 
buffer (Promega) at room temperature for 30 min. Fire?y 
and renilla luciferase activities Were measured by a Dual 
luciferases assay system using a TD-20/20 Luminometer 
(Promega). The mutant promoter activities Were compared 
to the Wild type promoter based on the normaliZed luciferase 
expression. Data Were evaluated using a statistical analysis 
system (SAS Institute Inc., Cary, NC). Analysis of vari 
ances Was performed for multiple comparison of each 
dependent variable. A p value <0.01 Was considered to be 
statistically signi?cant. 
The normaliZed luciferase reporter activities observed by 
the present inventors indicates that the mutations in the 
prompter signi?cantly reduced promoter activity (FIG. 7). 
Compared to the normal promoter activities, the mutated 
promoter activities decreased by more than 50% in the pGL3 
constructs and 90% in the pGL3-enhancer constructs, 
respectively. Multiple independent transfections Were per 
formed With similar results. 
Dnase I Footprinting Analysis 
Dnase I Footprinting analysis Was performed to detect 
possible changes in the binding pattern of transcription 
factors due to the mutations found in the promoter region of 
the human MnSOD gene from the tumor cell lines. Brie?y, 
the promoter region (—210 to +24) Was subcloned into a 
pUC18 plasmid betWeen Kpn I and Hind III sites. A sac 
I/Hind III fragment Was isolated from a 2% agarose gel in 
0.5>< Tri-borate buffer using a dialysis tubing (Gibco BRL) 
and dephosphorylated by an alkaline phosphates from calf 
intestinal (CIP, NeW England Biolabs). The puri?ed frag 
ment Was labeled With >\,-32P at 5‘ hydroXyl terminus by T4 
polynucleotide kinase (Promegaiand digested With Kpn I to 
generate a single end-labeled fragment. Puri?ed SP-1 and 
AP-2 proteins (Promega) Were incubated With each labeled 
promoter fragment, and the DNA Was partially digested by 
RNAse-Free DNAse. The samples Were separated on a 6% 
polyacrylamide sequencing gel. The gel Was vacuum dried 
and eXposed to an X-ray ?lm (Eastman Kodak Co.) at —70° 
C. for 16 h. 
Footprints Were observed at multiple binding sited for 
Sp-1 and AP-2 Within the promoter fragment (FIG. 8). One 
predicted SP-1 site close to the transcription initiation site 
Was apparently Weak and could not be detected. In the 
normal promoter fragment (FIG. 8). One predicted SP-1 site 
close to the transcription initiation site Was apparently Weak 
and could not be detected. In the normal promoter fragment, 
?ve strong protected regions Were observed With AP-2 
protein that corresponded to sites 1, 2, 3, 5 and 6. Some AP-2 
binding sites also overlap SP-1 binding sites (SP-1/AP-2). 
When AP-2 protein Was used With the mutant promoter 
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fragment, an additional AP-2 protected site Was observed 
(region 4 in FIG. 8) Which is consistent With the result from 
the computerized search. HoWever, footprinting did not 
shoW elimination of an AP-2 binding site by the C to T 
transition at —102. No change Was found in the SP-1 binding 
pattern. 
Although the footprinting assay shoWs transcription fac 
tor binding to a given DNA sequence, it is also likely that 
other interactions could be observed under in-vivo condi 
tions due to cooperative binding With other factors, and the 
formation of secondary and tertiary DNA structure arising 
out of interaction With nonadjacent sites and DNA-looping 
(Su et al. 1991) or DNA-bending (Ikeda) et al. 1993). It is 
possible that mutations in the promoter regions, Which affect 
transcriptional activity eXert this effect through alteration of 
promoter region secondary structures resulting from the 
disruption of DNA-protein as Well as DNA-DNA interac 
tions (Thomsen et al, 1994) study of secondary structure of 
CMV IE gene). 
The present inventors propose that a putative DNA loop 
ing structure could be formed through the surrounding 
sequences in the human MnSOD promoter as illustrated in 
FIG. 9. In this case, the eleven unpaired guanosine loop 
might provide a speci?c binding domain for activation of 
transcription. This loop structure contains three SP-1 and 
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AP-2 binding sites that are required for basal transcription of 
the gene. Deletion of this entire region has resulted in a 
greater than 90% decrease of transcriptional activity. ToW of 
the three mutations located in this region might interfere 
With the formation of the secondary structure, especially the 
C to T transition at —102 may result in an alteration of he 
putative loop structure. These ?ndings suggest that other 
mutations Which affect DNA secondary structure may be 
found Within the MnSOD promoter region Which similarly 
impair transcriptional activity by affecting DNA-protein or 
protein-protein interaction, and thus impairing treatment of 
polymerase. Accordingly, the present invention is not lim 
ited in scope to the three mutations detailed herein, but s also 
directed to the detection and treatment of other mutations, 
eXerting similar effects, Within the MnSOD promoter region. 
All of the references cited herein are hereby incorporated 
in their entireties by reference. 
While this invention has been described With an emphasis 
upon preferred embodiments, it Will be obvious to those or 
ordinary skill in the art that variations of the preferred 
embodiments may be used and that it is intended that the 
invention may be practiced otherWise that as speci?cally 
described herein. Accordingly, this invention includes all 
modi?cations encompassed Within the spirit and scope of the 
invention as de?ned by the folloWing claims. 
SEQUENCE LISTING 
<l60> NUMBER OF SEQ ID NOS: l2 
<2 10> 
<2ll> 
<2 12> 
SEQ ID NO 1 
LENGTH: 23 
TYPE: DNA 
ORGANISM: synthetic construct 
<400> SEQUENCE: l 
gcacatcact tcagtctagg agt 
SEQ ID NO 2 
LENGTH: 21 
TYPE: DNA 
ORGANISM: synthetic construct 
<400> SEQUENCE: 2 
ggctagttag gaagctggta c 
SEQ ID NO 3 
LENGTH: 22 
TYPE: DNA 
ORGANISM: synthetic construct 
<400> SEQUENCE: 3 
tccagttctc atagctagtg cc 
SEQ ID NO 4 
LENGTH: 23 
TYPE: DNA 
ORGANISM: synthetic construct 
<400> SEQUENCE: 4 
atatgatgga aggtagcagg tgc 
<2 10> SEQ ID NO 5 
23 
21 
22 
23 
11 
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<2ll> LENGTH: 
<2 12> TYPE: 
23 
DNA 
<2 13> ORGANISM: synthetic construct 
<400> SEQUENCE: 5 
ttaccggaag cctagtcatc ctt 
TYPE: 
SEQ ID NO 6 
LENGTH: 21 
DNA 
SEQUENCE: 6 
tgcctgtctg ccgtacttga g 
TYPE: 
SEQ ID NO 7 
LENGTH: 24 
DNA 
SEQUENCE: 7 
gccttcgggc cgtaccaact ccaa 
TYPE: 
SEQ ID NO 8 
LENGTH: 25 
DNA 
SEQUENCE: 8 
ctagtgctgg tgctaccgct gatgc 
TYPE: 
SEQ ID NO 9 
LENGTH: 35 
DNA 
SEQUENCE: 9 
ORGANISM: synthetic construct 
ORGANISM: synthetic construct 
ORGANISM: synthetic construct 
ORGANISM: synthetic construct 
cggggtacca caggcacgca gggcaccccc ggggt 
TYPE: 
SEQUENCE: 
SEQ ID NO 10 
LENGTH: 33 
DNA 
10 
ORGANISM: synthetic construct 
ggaagatctg ccgaagccac cacagccacg agt 
TYPE: 
<400> 
ggatccttac 
ctttgggagg 
acatggtgaa 
cctgtaatcc 
aggttgcagt 
tgattcggaa 
ccttcccctt 
SEQUENCE: 
SEQ ID NO 11 
LENGTH: 3663 
DNA 
11 
aatggagata 
Ctgaggcagg 
accccatctc 
cagctactca 
gagccgagat 
agaaaaaata 
gcctagaagg 
ORGANISM: Homo sapiens 
gtggggccag 
cagatcactt 
cactaaaaat 
ggaggctaag 
cgcaccactg 
aaaaaaggtt 
gagatgaggt 
gcatggtggc 
cagtctagga 
acaaaaatta 
gcaggagaat 
cactccagcc 
gggggagaca 
tcatgcctgt 
gttcgagacc 
gccaggcatg 
cacttgaact 
cagcaacaaa 
gtgggagccc 
gtggaagcta 
aatcccagca 
agcctggcca 
gtggcacgca 
(3519951991199 
gcaagactct 
agacttttgt 
ttatggacca 
23 
21 
24 
25 
35 
33 
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420 
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gcctcctgtc ctggaatagg tcccaaggtc ggcttacttg caaagcaagg gtacggcgca 2820 
agagtactga atacgggttg gaagggcgct ggctctaccc tcagctcata ggccggctgg 2880 
gcggcgctga ccagcagcta ggccccgtct tccctaggaa cggccacggg ggccctggga 2940 
gggtatgaat gtctttttgc agtgaggcct ctggaccccg cggccccccg gcagcgcaac 3000 
caaaactcag gggcaggcgc cgcagccgcc tagtgcagcc agatccccgc cggcaccctc 3060 
aggggcggac cggaggcagg gccttcgggc cgtaccaact ccaagggggc aggggccgcc 3120 
tcccttcggc cgcgcgccac tcaagtacgg cagacaggca gcgaggttgc cgaggccgag 3180 
gctagcctgc agcctccttt ctcccgtgcc ctgggcgcgg ggtgtacggc aagcgcgggc 3240 
gggcgggaca ggcacgcagg gcacccccgg ggttgggcgc ggcgggcgcg gggcggggcc 3300 
Cgcggggggg ggggcggggc ggcggtgccc ttgcggcgca gctggggtcg Cggccctgct 3360 
ccccgcgctt tcttaaggcc cgcgggcggc gcaggagcgg cactcgtggc tgtggtggct 3420 
tcggcagcgg cttcagcaga tcggcggcat cagcggtagc accagcacta gcagcatgtt 3480 
gagccgggca gtgtgcgggt gagaagaaag gggacccggt cacgcgccca agggcgaagg 3540 
ggctcgcggc gggcagggcc tccgcggcaa tggcgacagt ggccgcaccg ggcctggcgg 3600 
gaccggggca cctgcaggcg gttctcccgg gagtgcccgg cgcggcggct ggagcgggga 3660 
tcc 3663 
<2 10> SEQ ID NO 12 
<2ll> LENGTH: 38 
<2 12> TYPE: DNA 
<2 13> ORGANISM: Homo sapiens 
<400> SEQUENCE: l2 
Cggggcgggg Cccgcggggg gggggggcgg ggcggcgg 38 
What is claimed is: 
1. A method for detecting the presence of mutation Within 
the MnSOD gene promoter region Wherein the mutation is 
associated With cancer comprising: 
(i) carrying out restriction fragment length polymorphism 
analysis on a DNA test sample; 
(ii) obtaining a restriction endonuclease digestion pattern 
from the procedure in step (i); and 
(iii) comparing results obtained in step (ii) With restriction 
endonuclease digestion pattern of a Wild-type MnSOD 
gene promoter, Wherein a difference in the restriction 
endonuclease digestion pattern indicates the presence 
of at least one mutation in the MnSOD gene promoter 
in the DNA test sample Wherein the mutation is asso 
ciated With cancer. 
2. The method of claim 1, Wherein the MnSOD gene 
promoter sequence is ?rst ampli?ed by polymerase chain 
reaction technique before step (i), Wherein said DNA test 
sample is digested With restriction enZyme Which cuts at a 
recognition sequence Within the promoter region, and 
Wherein the resulting restriction endonuclease digestion 
pattern is visualiZed by electrophoresis, and staining With an 
appropriate DNA binding dye. 
3. The method of claim 1, Wherein the restriction endo 
nuclease digestion pattern folloWing restriction enZyme 
treatment is visualiZed by Southern Blot analysis Wherein 
after gel electrophoresis, the DNA is adsorbed to an appro 
priate membrane and hybridiZed With labeled oligonucle 
otide probes complementary to MnSOD gene promoter 
enhancer sequences. 
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4. A method for detecting MnSOD gene promoter muta 
tion Wherein the mutation is associated With cancer com 
prising: 
i) sequencing a test sample DNA comprising the MnSOD 
gene promoter; and 
ii) comparing the sequence obtained in step With a 
Wild-type sequence, Wherein a difference in the 
sequence indicates the presence of at least one mutation 
in the MnSOD gene promoter in the DNA test sample 
Wherein the mutation is associated With cancer. 
5. A method for detecting MnSOD gene promoter muta 
tion by PCR analysis Wherein the mutation is associated 
With cancer comprising: 
(i) making oligonucleotide primer complementary to the 
MnSOD gene promoter sequence containing one or 
more of the mutations; and 
ii) carrying out PCR procedure to amplify a sequence, 
Wherein the presence of PCR ampli?ed product indi 
cates at least one mutation in the MnSOD gene pro 
moter in the DNA Wherein the mutation is associated 
With cancer. 
6. A method for detecting MnSOD gene promoter muta 
tion Wherein the mutation is associated With cancer com 
prising: 
(i) admiXing a test DNA sample comprising MnSOD gene 
promoter With at least one transcription factor compris 
ing SP-1, AP-2 or NF-KB under conditions that facili 
tate DNA-protein binding; 
(ii) carrying out a DNA footprinting analysis, Wherein a 
footprinting pattern is obtained for the test sample DNA 
in step and; 
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(iii) comparing the footprinting pattern obtained in step 
(ii) With a footprinting pattern of a Wild-type MnSOD 
gene promoter, Wherein a difference in the footprinting 
pattern indicates the presence of at least one mutation 
in the MnSOD gene promoter in the DNA test sample 
Wherein the mutation is associated With cancer. 
7. A method for detecting MnSoD gene promoter muta 
tion Wherein the mutation is associated With cancer com 
prising: 
(i) admiXing a test DNA sample comprising MnSOD gene 
promoter With at least one transcription factor compris 
ing SP-l, AP-2 or NF-KB under conditions that facili 
tate DNA-protein binding; 
(ii) carrying out a DNA mobility shift analysis, Wherein an 
electrophoretic mobility pattern is obtained for the test 
sample DNA in step and; 
(iii) comparing the electrophoretic mobility pattern 
obtained in step (ii) With an electrophoretic mobility 
pattern of a Wild-type MnSOD gene promoter, Wherein 
a difference in the electrophoretic mobility pattern 
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indicates the presence of at least one mutation in the 
MnSOD gene promoter in the DNA test sample 
Wherein the mutation is associated With cancer. 
8. A method for detecting the presence of mutation Within 
the MnSOD gene promoter region Wherein the mutation is 
associated With cancer comprising: 
(i) linking a reporter gene 3‘ to the MnSOD gene promoter 
region in the DNA test sample; 
(ii) assaying for expression of the reporter gene; and 
(iii) comparing results obtained in step (ii) With level of 
reporter gene eXpression obtained using Wild-type 
MnSOD gene promoter, Wherein a difference in the 
level of reporter gene eXpression indicates the presence 
of at least one mutation in the MnSOD gene promoter 
in the DNA test sample Wherein the mutation is asso 
ciated With cancer. 
9. The method according to claim 8, Wherein said reporter 
gene is a luciferase gene. 
* * * * * 
